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SPECIFIC AIM
.5-lipoxygenase (5LOX) is the key enzyme in the
synthesis of inflammatory leukotrienes (LTs) from ara-
chidonic acid. We had previously found that hyperglu-
cocorticoidemia or dexamethasone treatment increase
5LOX expression in the rat brain in vivo. The aim of
this study was to characterize in detail the stimulatory
action of dexamethasone on 5LOX expression in neu-
ral cultures in vitro.
PRINCIPAL FINDINGS
1. Dexamethasone increases 5LOX mRNA and
protein content in primary cultures of rat cerebellar
granule neurons (CGN) in a concentration- and time-
dependent manner
Exposure of CGN to dexamethasone increased the
content of both 5LOX mRNA (assayed by quantitative
RT-PCR) and 5LOX protein (Western blotting). These
increases were concentration dependent and became
statistically significant with 100 nM dexamethasone.
Time course studies revealed that dexamethasone treat-
ment increased the content of 5LOX mRNA and
protein as early as 3 h and that these increases persisted
for at least 24 h of dexamethasone treatment (Fig. 1).
2. Dexamethasone increases the capacity of CGN
to produce cysteinyl leukotrienes (cysLTs)
The capacity of CGN to produce LTs was assayed by
enzyme-linked assay, i.e., by determination of cell-free
supernatants for the predominant 5LOX products
LTB4 and cysLTs (i.e., LTC4, LTD4, and LTE4). Cul-
tures were treated with 1 mM dexamethasone for 24 h
(controls were treated with a vehicle for the same
period of time). In the last 15 min of treatment,
cultures were supplemented with 10 mM arachidonic
acid (substrate for LT synthesis) and 2 mM A23187
(calcium ionophore; calcium is required for full 5LOX
enzymatic activity). In the absence of added arachi-
donic acid, we did not detect LTs in the culture
medium even if these cultures were treated with
A23187. After adding arachidonic acid and A23187, we
readily detected cycLTs but not LTB4 (the lower limit
of detection was 13 pg/ml) and the content of cysLTs
was greater in cultures pretreated with dexamethasone
than in the corresponding controls: vehicle 5 45.8 6
3.7; dexamethasone 5 64.7 6 5.7* (pg/ml; n58 per
group; *P,0.01). We detected LTB4 (;20 pg/ml) in
only a few samples from dexamethasone-pretreated
cultures.
3. Dexamethasone-up-regulated 5LOX expression
requires the glucocorticoid receptor (GR)
We verified the expression of GRs in our preparation of
CGNs with a specific anti-GR antibody. Using antisense
technology, we significantly reduced the content of GRs
in CGN cultures. GR antisense (AS) and the corre-
sponding scramble (SCRM) oligonucleotides were in-
jected directly into the culture medium twice at 12 h
intervals. Twelve hours after the second treatment, cells
were harvested for GR protein measurements. Applica-
tion of antisense to GRs reduced the content of GR
protein by more than 50% compared with SCRM-
treated controls. Thus, we used antisense methodology
to investigate whether alterations in GR content in
CGN also alter the effects of dexamethasone on 5LOX
expression (i.e., mRNA and protein levels). When GR
AS or SCRM oligonucleotides were coadministrated
with dexamethasone, GR AS but not SCRM suppressed
the dexamethasone-induced increase in 5LOX mRNA
and protein content (Fig. 2).
To further investigate whether the stimulatory effect
of dexamethasone on 5LOX expression occurs via the
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GRs, we used the GR antagonist RU486. After coadmin-
istration of 1 mM dexamethasone (or its vehicle) and 1
mM RU486 (or its vehicle) to CGNs for 24 h, 5LOX
mRNA and protein levels were quantified. We found
that RU486 significantly reduced dexamethasone-stim-
ulated 5LOX expression. On the other hand, RU486
did not alter the basal levels of 5LOX mRNA and
protein (Fig. 2).
4. Dexamethasone increases the half-life of 5LOX
mRNA in CGNs
It has been suggested that the stimulatory action of
dexamethasone on gene expression may include both
increased transcription and post-transcriptional effects,
such as prolongation of an mRNA’s half-life. Thus, we
examined 5LOX mRNA stability in CGN cultures
treated for 24 h with dexamethasone or its vehicle and
estimated the half-life of 5LOX mRNA after the inhibi-
tion of gene transcription with actinomycin D. Cul-
tured neurons were treated with dexamethasone or its
vehicle for 24 h before the addition of actinomycin D
(10 mg/ml). Total RNA was isolated from vehicle- and
dexamethasone-treated cells at different times after
actinomycin D and 5LOX mRNA levels were measured
by quantitative RT-PCR. The half-life (t1/2) of the
5LOX mRNA in vehicle-treated cells was 4.0 6 0.1 h,
whereas in dexamethasone-treated CGNs the t1/2 was
5.8 6 0.2 h (i.e., 50% longer; n53; P,0.01).
CONCLUSIONS AND SIGNIFICANCE
The results obtained in this study using primary cul-
tures of rat cerebellar cells confirm our previous find-
ings in the rat cerebellum in vivo: dexamethasone
treatment increased the content of 5LOX mRNA and
protein in cells of the mammalian central nervous
system (CNS). However, we selected the in vitro system
because it is better suited to mechanistic studies. Thus,
the stimulatory effect of dexamethasone on 5LOX in
CGNs was observed with concentrations as low as 100
nM, suggesting that 5LOX up-regulation occurs at
physiologically relevant concentrations of glucocorti-
coid hormones.
Many of the effects of corticosteroids in the CNS are
believed to be mediated via two types of corticosteroid
receptors (mineralocorticoid receptors and GRs) to
which dexamethasone binds. Previous studies with tri-
tiated dexamethasone autoradiography and immuno-
histochemistry demonstrated nuclear localization of
GRs in cerebellar granule cells in vivo. The functional
involvement of GRs in the regulation of 5LOX expres-
sion in CGNs in vitro is indicated by our findings in
experiments with GR antisense oligonucleotides and
with the GR antagonist RU486; both were effective in
inhibiting the up-regulation of 5LOX expression by
dexamethasone. We performed these studies using two
complementary methods because a single-method ap-
proach might generate inconclusive results, i.e., RU486
is a potent antagonist for both intracellular GRs and for
progesterone receptors because it binds with high
affinity to these receptors and causes transconforma-
tional differences in their ligand binding domains.
Since GR antisense and RU486 both prevented dexa-
methasone from up-regulating 5LOX expression, it can
be concluded that genomic mechanisms rather than a
Figure 1. Effect of dexamethasone (Dex) on 5LOX mRNA and
protein contents in primary cultures of rat cerebellar granule
neurons (CGN). These cultures were treated with increasing
concentrations of Dex for 24 h (A, B), or with 1 mM Dex for the
periods indicated (C, D). Experiments were performed in 3–4
different culture preparations (A, B; mean6se; *P,0.01 vs.
control; Ctrl) or in 2 different culture preparations (C, D; means
expressed as % of the corresponding time controls: each time
point had its own vehicle-treated group).
Figure 2. Glucocorticoid receptors are needed for stimulatory
action of dexamethasone on 5LOX expression: antisense and
pharmacological experiments. The GR antisense (AS: GGAT-
TCTTTGGAGTCCAT) and the corresponding control scram-
ble (SCRM: AATGCTCGCTTGATGTTG) oligonucleotides
were dissolved in the culture medium and added to the cells
twice (12 h intervals for 24 h; final concentration 10 mM);
cells were processed 12 h after the second application of
oligonucleotides; treatment with AS reduced the content of
GR-immunoreactive protein. Coadministration of dexameth-
asone (Dex; 1 mM) with oligonucleotides was performed in
panels A and B and with 1 mM RU486 (GR antagonist) in
panels C and D. Both AS and RU486 prevented the stimula-
tory action of Dex; SCRM was ineffective (n53 different
preparations; mean6se; P,0.05: *vs. Ctrl, #vs. Dex).
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nongenomic action that involves the activation of pu-
tative membrane receptors for glucocorticoids medi-
ated the effects of dexamethasone we observed in
CGNs. However, it should be stressed that no obvious
glucocorticoid response element has been found in the
sequence of the 5LOX gene and its promoter. Thus, it
remains to be established whether such a response
element is located elsewhere in the genome and in
relation to the 5LOX gene.
Using various in vitro models of cell cultures, others
have also observed 5LOX up-regulation in response to
dexamethasone treatment. For example, 5LOX mRNA
and protein were both increased after dexamethasone
treatment in human mast cells and in human mono-
cytes and THP-1 cells. In those cell cultures, dexameth-
asone also increased the capacity of these cells to
produce LTs, and the authors concluded that this
synthetic glucocorticoid increased 5LOX gene expres-
sion. Our primary cultures of CGNs express 5LOX and
the 5LOX-activating protein FLAP. Nevertheless, we
found that they do not produce detectable levels of LTs
unless provided with exogenous arachidonic acid.
When provided with arachidonic acid and in the pres-
ence of the calcium ionophore, these cells produced
cysLTs, and their capacity to synthesize cysLTs was
increased by dexamethasone pretreatment. Thus, we
also conclude that collectively our data on 5LOX
mRNA, 5LOX protein, and LT synthesis are consistent
with the proposed stimulatory action of dexamethasone
on 5LOX gene expression (Fig. 3).
Our finding that dexamethasone pretreatment pro-
longed the half-life of 5LOX mRNA suggests it is
possible that mechanisms that regulate RNA stability
could also contribute to the increase in 5LOX gene
expression we observed. Such mechanisms are also
likely to include a direct action of dexamethasone on
5LOX mRNA or on mRNA-selective proteins/enzymes.
Glucocorticoids have already been shown capable of
enhancing the stability of other mRNAs, such as that of
insulin receptors and growth hormone. Even though
the molecular mechanisms of the hormonal regulation
of RNA stability are not very well understood, it has
been speculated that glucocorticoids may induce a
factor that associates with an RNA element in the
39untranslated region (39UTR) of these genes.
The functional significance of our findings for the
physiology and/or pathology of the CNS remains to be
fully characterized. However, available data point to
possible roles for the 5LOX pathway in brain aging,
neurodegeneration, seizures, synaptic activity, neuro-
genesis, and neurodevelopment. It is also important to
elucidate whether enzymatic or even nonenzymatic
actions of 5LOX protein are relevant for CNS
functioning.
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Figure 3. Schematic presentation of main findings. At resting,
CGNs express glucocorticoid receptors (GR) as well as 5LOX
mRNA and protein. Exposure of CGN to dexamethasone
(DEX) increases 5LOX mRNA and protein expression and
results in the increased capacity of these cells to synthesize
cysLTs. The stimulatory action of DEX can be inhibited (2)
either by RU486 (GR antagonist) or by decreasing the cell
content of GR with the GR-specific antisense oligonucleotide
(AS).
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